News & Media

Press release
Medivir to present at the H.C. Wainwright 24th Annual Global Investment Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Pareto Securities´ Healthcare conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Pareto Securities´ Healthcare conference...

Read more
Press release
Medivir to present at the Erik Penser Bank Company Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Company...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2022

The clinical development of fostrox remains our focus  April – June Financial summary for the quarter Net turnover amounted to SEK...

Read more
Press release
Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ABGSC Life Science Summit...

Read more
Press release Regulatory
Resolutions at the Annual General Meeting in Medivir on 5 May 2022

Medivir Aktiebolag (publ) held its annual shareholders’ meeting today on 5 May 2022. The annual general meeting was held by physical...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2022

Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide January – March Financial summary for the...

Read more
Press release
Medivir to present at the Redeye Orphan Drugs Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference...

Read more
Press release
Medivir to participate at the Kempen Life Sciences Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the Kempen Life Sciences Conference,...

Read more
Press release Regulatory
Medivir 2021 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2021 now is available at the...

Read more
Press release Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more